Litcius/Paper detail

A tumor-associated splice-isoform of <i>MAP2K7</i> drives dedifferentiation in MBNL1-low cancers via JNK activation

Debleena Ray, Yu Chye Yun, Muhammad Idris, Shanshan Cheng, Arnoud Boot, Tan Bee Huat Iain, Steve Rozen, Patrick Tan, David Epstein

2020Proceedings of the National Academy of Sciences40 citationsDOIOpen Access PDF

Abstract

Significance Targeting stem-like cells in cancer is critical to overcoming resistance and relapse post chemotherapy or immunotherapy. We elucidate an alternative-splicing driven mechanism of cancer dedifferentiation and define a molecular context wherein stem-like tumor cells show enhanced susceptibility to JNK inhibition. MBNL1 and MAP2K7 ∆exon2 can prognosticate patients for JNK inhibition that can render stem-like tumor cells susceptible to therapy.

Topics & Concepts

Cancer researchContext (archaeology)Stem cellRNA splicingAlternative splicingGene isoformCancer stem cellImmunotherapyMedicineCancerBiologyChemistryCell biologyInternal medicineGeneGeneticsPaleontologyRNARNA Research and SplicingRNA modifications and cancerinterferon and immune responses
A tumor-associated splice-isoform of <i>MAP2K7</i> drives dedifferentiation in MBNL1-low cancers via JNK activation | Litcius